• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vyepti (eptinezumab-jjmr)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vyepti (eptinezumab-jjmr)

  • Profile

Profile

Contact Information

Contact: Lundbeck
Website: https://www.vyepti.com/

Currently Enrolling Trials

    Show More

    General Information

    Vyepti (eptinezumab-jjmr) is a calcitonin gene-related peptide antagonist.

    Vyepti is specifically indicated for the preventive treatment of migraine in adults.

    Vyepti is supplied as a solution for intravenous administration. Vyepti  requires dilution prior to administration. The recommended dose is 100 mg administered by intravenous infusion every 3 months. Some patients may benefit from a dosage of 300 mg administered by intravenous infusion every 3 months.

    Mechanism of Action

    Vyepti (eptinezumab-jjmr) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

    Side Effects

    Adverse effects associated with the use of Vyepti may include, but are not limited to, the following:

    • nasopharyngitis
    • hypersensitivity

    Clinical Trial Results

    The FDA approval of Vyepti was based on two phase III randomized, placebo controlled clinical trials (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine). In both studies, patients were randomized to receive placebo, Vyepti 100 mg, or Vyepti 300 mg. The primary endpoint was the change from baseline in mean monthly migraine days (MMD) over months 1-3. Patients were allowed to use concurrent acute migraine or headache medications. In PROMISE-2, the study population included patients with a dual diagnosis of chronic migraine and medication overuse headache attributable to acute-medication overuse of triptans, ergotamine, or combination analgesics greater than 10 days per month.

    PROMISE-1: A total of 665 patients were randomized to receive placebo or Vyepti every 3 months for 12 months. Mean migraine frequency at baseline was approximately 8.6 migraine days per month and was similar across treatment groups. The Mean change from baseline in MMD with Vyepti compared with placebo from months 1-3 was: -3.9 days for 100 mg, -4.3 days for 300 mg and -3.2 days for placebo. Percent responders with at least 50 percent reduction in MMD in months 1-3 compared with placebo: 49.8 percent for 100 mg, 56.3 percent for 300 mg and 37.4 percent for placebo. Percent responders with at least 75 percent reduction in MMD in months 1-3: 22.2 percent for 100 mg , 29.7 percent for 300 mg and 16.2 percent for placebo. In addition, a greater percentage of placebo-treated patients had migraine on most days during the first 7 days of treatment compared to Vyepti -treated patients.

    PROMISE-2: A total of 1,072 patients were randomized to receive placebo (N=366), 100 mg Vyepti (N=356) or 300 mg Vyepti (N=350) every 3 months for 6 months. Mean migraine frequency at baseline was approximately 16.1 migraine days per month and was similar across treatment groups. Mean change from baseline in MMD compared with placebo months 1-3: -7.7 days for 100 mg, -8.2 days for 300 mg and -5.6 days for placebo. Percent responders with at least 50 percent reduction in MMD in months 1-3 compared with placebo: 57.6 percent for 100 mg, 61.4 percent for 300 mg and 39.3 percent for placebo. Percent responders with at least 75 percent reduction in MMD in months 1-3: 26.7 percent for 100 mg, 33.1 percent for 300 mg and 15.0 percent for placebo. A greater percentage of placebo-treated patients had migraine on each individual day during the first 7 days of treatment compared to Vyepti-treated patients.

    Approval Date: 2020-02-01
    Company Name: Lundbeck
    Back to Listings

    Upcoming Events

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing